[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353480-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353480-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","metformin-suppresses-metastatic-potential-and-sensitizes-ovarian-cancer-cells-to-chemotherapeutics","Metformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics","","The failure of current therapeutics to elicit a durable response in metastatic ovarian cancer patients highlights the urgent need to develop more effective treatment strategies. In this study, metformin, an anti-diabetic drug, exhibits cytotoxic effects across a broad panel of ovarian cancer cell lines. Transcriptomic analyses show modulation of metastatic-associated pathways including migration, extracellular matrix remodeling, and responses to chemotherapy. Metformin impairs migration and invasion in Matrigel and reduces multicellular aggregation, with modest carboplatin sensitization and enhanced efficacy of several FDA-approved drugs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/metformin-suppresses-metastatic-potential-and-sensitizes-ovarian-cancer-cells-to-chemotherapeutics/353480/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/metformin-suppresses-metastatic-potential-and-sensitizes-ovarian-cancer-cells-to-chemotherapeutics/353480.png","ImageObject",300,407,{"name":42,"@type":43},"MrHarris58","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem in metastatic ovarian cancer does this study address?","Question",{"text":63,"@type":64},"The study targets the lack of durable therapeutic responses in metastatic ovarian cancer, emphasizing the need for more effective strategies to overcome chemoresistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does metformin affect ovarian cancer cells in this work?",{"text":68,"@type":64},"Metformin shows cytotoxic effects, reduces viability and proliferation, and modulates pathways related to metastatic progression, including cell migration and extracellular matrix remodeling.",{"name":70,"@type":61,"acceptedAnswer":71},"Does metformin improve sensitivity to chemotherapy such as carboplatin?",{"text":72,"@type":64},"Metformin produces a modest increase in carboplatin sensitivity, and systematic screening identifies several FDA-approved agents whose efficacy is enhanced by metformin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353480,1790387603,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nMetformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics  \nMegha J. Pandya 1, Ayokunnumi Ogunsanya 1, Adedoyin Ajibade 1 and Achuth Padmanabhan 1,2, *  \nAcademic Editor: Stergios Boussios  \nReceived: 20 July 2026  \nRevised: 21 August 2026  \nAccepted: 24 August 2026  \nPublished: 30 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA; [meghajp1@umbc.edu](meghajp1@umbc.edu) (M.J.P.); [aogunsa2@umbc.edu](aogunsa2@umbc.edu) (A.O.); [aajibad1@umbc.edu](aajibad1@umbc.edu) (A.A.)  \n2 University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD 21201, USA  \n* Correspondence: [achuth1@umbc.edu](achuth1@umbc.edu); Tel.: +1-410-455-8949  \nAbstract  \nThe failure of current therapeutics to elicit a durable response in metastatic ovarian cancer patients highlights the urgent need to develop more effective treatment strategies. In this study, we demonstrate that the anti-diabetic drug metformin exerts cytotoxic effects across abroad panel of ovarian cancer cell lines. Transcriptomic analyses revealed that, in addition to reducing cell viability and proliferation, metformin modulates pathways associated with metastatic progression, including cell migration, extracellular matrix remodeling, and cellular responses to chemotherapeutic agents. Consistent with these molecular changes, metformin significantly impaired ovarian cancer cell migration and invasion through Matrigel. Furthermore, metformin diminished the ability of ovarian cancer cells to form multicellular aggregates, a key property that facilitates successful metastatic dissemination within the peritoneal cavity. Although metformin produced only a modest increase in carboplatin sensitivity, systematic screening of FDA-approved drugs identified several agents whose efficacy was enhanced by metformin, including drugs not currently used to treat ovarian cancer. Collectively, these findings demonstrate that metformin suppresses metastatic phenotypes and enhances therapeutic vulnerability in ovarian cancer cells, supporting its potential repurposing as a combination therapy to improve treatment outcomesin ovarian cancer.  \nKeywords: ovarian cancer; metastatic potential; metformin; therapeutic combination; carboplatin; drug repurposing; FDA-approved drugs  \n1. Introduction  \nOvarian cancer is an extremely lethal gynecologic malignancy with limited therapeutic options [1] . Due to the absence of reliable early diagnostic markers, the majority of patients continue tobe diagnosed with advanced metastatic disease [1] . First-line treatment for these patients includes cytoreductive surgery followed by chemotherapy using a combination of platinum and taxane-based compounds [2] . Although most patients respond well to this strategy initially, in over 85% of patients, the tumor relapses within 6 months [3] . Relapsed tumors are resistant to extant therapeutics, resulting in poor clinical outcomes [1,4,5] . The failure of extant therapeutics to provide durable responses highlights the urgent need to identify novel therapeutic strategies and drug combinations that will help overcome chemoresistance and improve clinical outcomes in ovarian cancer patients.  \nDrug repositioning or repurposing is the process of using an existing drug for the treatment of a medical condition for which it has not been previously used [6] . As  \nthese drugs have already undergone rigorous safety evaluation, their transition into the clinic can be achieved much more efficiently and at lower costs as compared to conventional drug development routes. Metformin is an FDA-approved first-line therapeutic for type 2 diabetes [7–9] . Metformin has been in clinical use for over 70 ","cbCaiotYQyuBmMMX","https://ap.wps.com/l/cbCaiotYQyuBmMMX","pdf",13948911,17,"English","# Abstract\n# Introduction","[{\"question\":\"What problem in metastatic ovarian cancer does this study address?\",\"answer\":\"The study targets the lack of durable therapeutic responses in metastatic ovarian cancer, emphasizing the need for more effective strategies to overcome chemoresistance.\"},{\"question\":\"How does metformin affect ovarian cancer cells in this work?\",\"answer\":\"Metformin shows cytotoxic effects, reduces viability and proliferation, and modulates pathways related to metastatic progression, including cell migration and extracellular matrix remodeling.\"},{\"question\":\"Does metformin improve sensitivity to chemotherapy such as carboplatin?\",\"answer\":\"Metformin produces a modest increase in carboplatin sensitivity, and systematic screening identifies several FDA-approved agents whose efficacy is enhanced by metformin.\"}]","Metformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics | PDF",1790105649,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/891aa957f4d07c14fd5178b045c9e3f9.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b0fd31a52f1e507f5b9f0c7772913d3.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e1832b6e1f3a369fb12616f18309970.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72391e1604b761a56996f699d7b79137.webp",980,1385]